Coeptis Therapeutics Receives Nasdaq Non-Compliance Notice for Delayed Annual Meeting, Plans Swift Resolution
Summary
Coeptis Therapeutics received a Nasdaq non-compliance notice for not holding its annual meeting, but has scheduled the meeting for January 30, 2026, to regain compliance.
Key Events
-
Nasdaq Non-Compliance Notice Received
On January 12, 2026, Coeptis Therapeutics Holdings, Inc. received a letter from Nasdaq indicating non-compliance with Listing Rules 5620(a) and 5810(c)(2)G).
-
Violation for Delayed Annual Meeting
The non-compliance stems from the company's failure to hold an annual meeting of shareholders within twelve months of its fiscal year end of December 31, 2024.
-
Company's Plan to Regain Compliance
The company has 45 days to submit a compliance plan. Coeptis Therapeutics has already scheduled its annual meeting for January 30, 2026, which it believes will resolve the issue and regain compliance.
Analysis
Coeptis Therapeutics Holdings, Inc. received a formal notice from Nasdaq regarding non-compliance with listing rules due to its failure to hold an annual meeting of shareholders within the required timeframe. While such notices are serious and can lead to delisting if not addressed, the company has already scheduled its annual meeting for January 30, 2026. This proactive step is expected to bring the company back into compliance, mitigating the immediate risk of delisting. Investors should monitor the successful execution of the annual meeting and subsequent confirmation of compliance from Nasdaq.
At the time of this filing, COEP was trading at $12.67 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $72M. The 52-week trading range was $6.26 to $21.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.